Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Abelson kinase (c‐abl) and platelet‐derived growth factor (PDGF) are key players in the pathogenesis of systemic sclerosis (SSc). The aim of the present study was to evaluate the antifibrotic potential of dasatinib and nilotinib, 2 novel inhibitors of c‐abl and PDGF, which are well tolerated and have recently been approved. Dasatinib and nilotinib dose‐dependently reduced the mRNA and protein levels of extracellular matrix proteins in human stimulated dermal fibroblasts from SSc patients (IC 50 of 0.5–2.0 nM for dasatinib and 0.8–2.5 nM for nilotinib). In a mouse model of bleomycin‐induced dermal fibrosis, dasatinib and nilotinib potently reduced the dermal thickness, the number of myofibroblasts, and the collagen content of the skin in a dose‐dependent manner at well‐tolerated doses. These data indicate that dasatinib and nilotinib potently inhibit the synthesis of extracellular matrix in vitro and in vivo at biologically relevant concentrations. Thus, we provide the first evidence that dasatinib and nilotinib might be promising drugs for the treatment of patients with SSc.—Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jüngel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., Distler, J. H. W. Dual inhibition of c‐abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22, 2214–2222 (2008)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthemore, this compound strongly lowered myofibroblasts formation and dermal thickness in bleomycin induced skin fibrosis in mice (199).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [199]
In the citing paper
“In dermal fibroblasts, nilotinib inhibits TGFβ- or PDGF-induced collagen production in a dose dependent manner (199).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [199]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 30 · Cited by 187
Metadata
- Authors
- Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jüngel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., & Distler, J. H. W.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Department of Rheumatology Kaunas Medical University Hospital Kaunus Lithuania
- University of Zurich (CH)
- ORCID
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2008-03-07
- Volume
- 22
- Issue
- 7
- Pages
- 2214-2222
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2030619805
- Cited by
- 187
- References
- 30
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 6 · 2020: 6 · 2019: 13 · 2018: 10 · 2017: 15 · 2016: 10 · 2015: 11 · 2014: 4 · 2013: 12 · 2012: 21
- FWCI
- 15.61
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Elan (53410022)
- German-Russian Interdisciplinary Science Center (A20)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- dasatinib, nilotinib, c-Abl kinase, PDGF receptor, systemic sclerosis, skin fibrosis, antifibrotic therapy, extracellular matrix synthesis, dermal fibroblasts, myofibroblasts, bleomycin-induced fibrosis, tyrosine kinase inhibitors
- MeSH terms
- Dasatinib, Adult, Aged, Biopsy, Cells, Cultured, Fibroblasts, Humans, Middle Aged, Pyrimidines, Scleroderma, Systemic, Skin, Thiazoles, Signal Transduction, Proto-Oncogene Proteins c-abl, Receptors, Platelet-Derived Growth Factor, Age of Onset, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. https://app.cochat.ai/papers/10.1096/fj.07-105627
- The paper
- Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jüngel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., & Distler, J. H. W. (2008). Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. The FASEB Journal. https://doi.org/10.1096/fj.07-105627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.